Feb 14, 2019
Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors
Jan 09, 2019
EUSA Pharma Completes Acquisition of Global Rights to SYLVANT® (Siltuximab) and Presents Company Update at 37th J.P. Morgan Healthcare Conference
Dec 10, 2018
Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million
Nov 07, 2018
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Oct 29, 2018
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Oct 23, 2018
Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018
Sep 14, 2018
Atlantis Healthcare Wins Gold PM360 Trailblazer Award for Best Persistence/Adherence Program
Sep 11, 2018
Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch
Aug 29, 2018
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Aug 06, 2018
Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies
Aug 01, 2018
Parkinson's Disease Market 2018 by Phase of Development, Type of Treatment, Type of Molecule, Mechanism of Action, Route of Administration, and Leading Players
Jul 24, 2018
Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018
Jul 11, 2018
EUSA Pharma Announces Sale of Critical Care Business to SERB Pharmaceuticals
Jun 27, 2018
Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 06, 2018
Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference
Jun 03, 2018
Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
May 10, 2018
Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting
Apr 24, 2018
Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018
Mar 07, 2018
EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors
Mar 06, 2018
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March